On December 24, Gelonghui reported that Shanxi C&Y Pharmaceutical Group (300254.SZ) announced that it will hold the 24th meeting of the Fifth Board of Directors and the 18th meeting of the Fifth Supervisory Board on December 24, 2024, to review and approve the "Proposal for Postponing Some Fundraising Projects". It was agreed that under the condition that the implementation subject, implementation method, fundraising purpose, and investment scale of the fundraising projects do not change, the timeline for the "Pharmaceutical Research and Development Project for the New Drug Rosuhatastat and Capsules" in the funds raised through the issuance of stocks to specific entities in the 2020 fiscal year will be extended to December 2026. The sponsoring institution has issued verification opinions, and the postponement of this fundraising project is within the approval authority of the Board of Directors and does not need to be submitted for review by the Shareholders' Meeting.
仟源医药(300254.SZ)：拟将“新药研发项目之药品罗沙司他及胶囊”延期至2026年12月
Shanxi C&Y Pharmaceutical Group (300254.SZ): plans to extend the "new drug research and development project of the pharmaceutical Rosabastat and capsules" to December 2026.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.